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Epigenetic mechanisms, especially DNA methylation and histone modifications, are 
dynamic processes that regulate the gene expression transcriptional program in normal 
and diseased states. The bromodomain and extraterminal (BET) protein family (BRD2, 
BRD3, BRD4, and BRDT) are epigenetic readers that, via bromodomains, regulate gene 
transcription by binding to acetylated lysine residues on histones and master transcriptional 
factors. Experimental data have demonstrated the involvement of some BET proteins in 
many pathological conditions, including tumor development, infections, autoimmunity, 
and inflammation. Selective bromodomain inhibitors are epigenetic drugs that block the 
interaction between BET proteins and acetylated proteins, thus exerting beneficial effects. 
Recent data have described the beneficial effect of BET inhibition on experimental renal 
diseases. Emerging evidence underscores the importance of environmental modifications 
in the origin of pathological features in chronic kidney diseases (CKD). Several cellular 
processes such as oxidation, metabolic disorders, cytokines, inflammation, or accumulated 
uremic toxins may induce epigenetic modifications that regulate key processes involved 
in renal damage and in other pathological conditions observed in CKD patients. Here, we 
review how targeting bromodomains in BET proteins may regulate essential processes 
involved in renal diseases and in associated complications found in CKD patients, such 
as cardiovascular damage, highlighting the potential of epigenetic therapeutic strategies 
against BET proteins for CKD treatment and associated risks.
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INTRODUCTION
Chronic kidney disease (CKD) is characterized by a loss of the nephron functionality. This pathological 
situation is triggered by an inflammatory response that damages the resident cells of the kidney, thus 
activating several intracellular mechanisms, which amplifies the renal damage and finally leads to 
fibrosis. Nowadays, the elevated presence of risk factors such as obesity, hypertension, diabetes, 
and aging increases the prevalence of CKD; currently, CKD is estimated to affect approximately 
10% of the EU population. When CKD progresses towards the end stage (ESRD), patients require 
a replacement therapy. Patients who do not receive a kidney transplant require dialysis treatment 
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(64% of patients), resulting in an annual cost of €15 billion to 
EU health systems. Furthermore, CKD has been established 
as public-health priority due the high risk of cardiovascular 
complications associated with the disease. Nowadays, therapeutic 
options against CKD are limited, hence the value of novel 
therapeutic options that can prevent the initial development 
of the pathology or its progression. Currently, there is several 
evidence of how the environmental modifications or altered 
pathological factors that appear during CKD (oxidative stress 
and inflammation, among others) could be induced by epigenetic 
modifications or changes. In renal pathology, the most widely 
studied epigenetic alterations are DNA methylation, histone 
modifications (acetylation, phosphorylation, methylation, 
 etc.), and changes in miRNAs levels (Morgado-Pascual et al., 
2018). These epigenetic changes regulate the transcription of 
many genes involved in the inflammatory and immune response, 
and other relevant process involved in renal pathology and in 
cardiovascular-related complications (Keating and El-Osta, 
2013; Morgado-Pascual et al., 2018).
The relevance of these investigations has led to the growing 
development of small molecules targeting enzymes responsible for 
“writing,” “reading,” or “erasing” of the epigenetic modifications. 
Among them, the bromo- and extraterminal (BET) proteins are 
epigenetic “readers,” which recognize and bind to the acetylated 
lysine in histones and other proteins. In this review, we will 
discuss the role of BET proteins in renal pathology and associated 
diseases such as cardiovascular damage, highlighting its potential 
role as a therapeutic target for CKD treatment.
BET Proteins
The BET family consists of four members; BRD2, BRD3, and 
BRD4, which are ubiquitously expressed, and BRDT, whose 
expression is limited to the male germ cell. These proteins are 
located in the nucleus of the cell, but the functional differences 
between them are not well defined (Markowski et al., 2017; 
Radwan et al., 2017). Bromodomains (BD) were discovered for 
the first time in studies on the gene Brama in Drosophila (Haynes 
et al., 1992) and there are now described at least 61 types of 
bromodomains encoded in the human genome. The structure of 
the bromodomains is formed by four helix packed with two loops 
of different length between their helices, BC and ZA (Figure 1). 
The hydrophobic pocket, formed by the BC and ZA loops, is 
coated with residues of Tyr97, Asp140, Val752, Ala757, Tyr760, 
Val763, Tyr802, and Tyr 809. The hydrophobic pocket is an ideal 
site for protein–protein interactions. It is located at one end of the 
packet of four helices, opposite the amino and carboxyl terminal 
zone of the protein (Jeanmougin et al., 1997). Bromodomains 
serve as regulators of the protein–protein interaction in different 
cellular processes such as transcription and chromatin remodeling 
(Sanchez et al., 2014). Furthermore, they are not only present in 
“reading” proteins, which are responsible for recognizing different 
epigenetic modifications (de la Cruz et al., 2005), but are also 
present in 46 different types of proteins such as acetyltransferases, 
chromatin-associated proteins, transcriptional coactivators, and 
methyltransferases (Dhalluin et al., 1999).
The structure of BET proteins includes a tandem of two 
conserved N-terminal bromodomains (BD1 and BD2), an 
extraterminal domain (ET), and a c-terminal domain (CTD) 
(Figure 1). The BDs are amino acidic hydrophobic regions 
where protein–protein interaction occurs, and by this region BD 
interact as an epigenetic “reader” (Wu and Chiang, 2007; Wang 
et al., 2017). The ET domain is responsible of the recruitment 
of different proteins that are components of the transcriptional 
complex. The CTD is only possessed by two of the family 
members of BET proteins (BRD4 and BRDT), and it is necessary 
for the recruitment of positive elongation factor (P-TEFb). BET 
proteins can bind to acetylated lysines of the histones located in 
the “super-enhancers” (DNA regions enriched with repressive 
acetylated H3K27 marks and RNA polymerase II) or promoter 
regions of the genes. After this binding, BET proteins, via CTD, 
participate in the recruitment of P-TEFb to the transcriptional 
complex (forming a heterodimer of CDK9 and cyclin T1 or T2). 
This union determines the degree of chromatin compaction, 
acting as a regulator of gene expression (Jang et al., 2005; Devaiah 
et al., 2012). In addition, BET proteins via bromodomain can 
also interact with acetylated lysine residues in other proteins 
such as transcription factors, regulating their function (Wang 
et al., 2018) (Figure 2).
BET proteins, which are epigenetic regulators of gene 
transcription, are strongly implicated in the regulation of cell 
Abbreviations: ET, extraterminal domain; iBETs, BET proteins inhibitors; 
NF-κB, nuclear factor-κB; UUO, unilateral ureteral obstruction; aa, Aminoacids; 
AAAs, abdominal aortic aneurysms; Acta2, α-smooth muscle actin; ALP, alkaline 
phosphatase; AngII, angiotensin II; ARA, II angiotensin II receptors type I 
antagonists; BAF, barrier to autointegration factor; BCL2, B-cell lymphoma 
2; BET, bromo extraterminal; BRD2, bromodomain-containing protein 2; 
BRD3, bromodomain-containing protein 3; BRD4, bromodomain-containing 
protein 4; BRDT, bromodomain testis-specific protein; BTBR, black and tan, 
brachyuric; CCL-20, chemokine (C–C motif) ligand 20; CCL2, chemokine 
(C–C motif) ligand 2; CCl4, carbon tetrachloride; RPGN, crescentic rapidly 
progressive glomerulonephritis; CCL5/RANTES, regulated on activation, 
normal T expressed and secreted; CIA, collagen-induced arthritis; CKD, chronic 
kidney disease; COPD, chronic obstructive pulmonary disease; CSF-1, colony 
stimulating factor 1; CTD, c-terminal domain; CVD, cardiovascular disease; 
CXCL10, chemokine (C-X-C motif) ligand 10; CXCL11, chemokine (C-X-C 
motif) ligand 11; DNA, deoxyribonucleic acid; EMT, epithelial–mesenchymal 
transition; ERK1, extracellular signal-regulated kinases 1; ERK2, extracellular 
signal-regulated kinases 2; ESRD, end stage renal damage; GATA3, trans-
acting T-cell-specific transcription factor 3; HDL, high density lipoprotein; HF, 
heart failure; HPMECs, human pulmonary microvascular endothelial cells; 
HSC, hepatic stellate cell; HUVECs, human umbilical cordon endothelial cells; 
IFNγ, interferon gamma; IL-10, interleukin-10; IL-17, interleukin-17; IL-18, 
interleukin-18; IL-1b, interleukin-1b; IL4, interleukin-4; IL6, interleukin-6; 
iNOS, inducible nitric oxide synthase; IPF, idiopathic pulmonary fibrosis; LDL, 
low density lipoprotein; LFs, lung fibroblast; LIF, leukemia inhibitory factor; 
LPS, lipopolysaccharide; LV, left ventricular; M1P1a, macrophage inflammatory 
protein 1α; MAECs, murine aortic endothelial cells; MAPK, mitogen-activated 
protein kinase kinase; MCAP, mitotic protein associated to cromatin; miRNA, 
small non-coding RNA molecule; MMP-9, matrix metalloproteinase 9; NFATc1, 
nuclear factor of activated T cell C1; Nkd2, naked cuticle homolog 2; OGD, 
oxygen/glucose deprivation; OPCs, oligodendrocyte-precursor cells; P-TEFb, 
positive elongation factor b; PE, phenylephrine; PI3K, phosphatidylinositol-
3-kinase; RANKL, receptor activator of nuclear factor kappa-B ligand; RORC, 
RAR related orphan receptor C; SAP, synapse-associated protein; STAT3, signal 
transducer and activator of transcription 3; TBX21, T-box transcription factor 
21; TGF-β, transforming growth factor β; TNF-α, tumor necrosis factor-α; TRAP, 
tartrate-resistant acid phosphatase; VCAM1, vascular cell adhesion molecule 1; 
α-SMA, alpha-smooth muscle actin.
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growth, differentiation, and inflammation (Figure 3). These 
proteins are located in the nucleus and regulate many cellular 
activities including gene transcription, DNA replication, cell-cycle 
progression, and, therefore, participate in tumor development, 
infections, autoimmunity, and inflammation (Boehm et al., 2013; 
Xu & Vakoc, 2014). Although some research has been carried out 
the functional differences between the distinct BET proteins are 
not well defined yet.
BRD4 the Most Studied BET Protein
The most comprehensively characterized BET member is BRD4 
(originally named mitotic protein associated with chromatin or 
FIGURE 1 | Bromodomain structure in the bromodomain and extraterminal (BET) family proteins.
FIGURE 2 | Bromodomain and extraterminal (BET) proteins recognize acetylated residues in histones or in other proteins such as transcription factors. BET proteins 
can recruit transcription factors in distant areas from the promoter of genes involved in different cellular processes.
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MCAP). BRD4 was identified in 1988 in studies on mammals as a 
coactivator protein involved in gene transcription (Huang et al., 
2009). Since then, several studies have demonstrated the role 
of BRD4 in several steps of the transcription hierarchy. BRD4 
was firstly described as a proliferative target in a cancer study 
of nuclear testis protein (NUT) midline carcinoma caused by 
the nuclear translocation of the BRD4-NUT oncogene product 
(Wang and You, 2015). The product of this gene acts by driving 
the cell in a permanent proliferative phase (French et al., 2008; 
Filippakopoulos et al., 2010). Initial studies described that BRD4 
recruits the p-TEFb complex to the promoter region of genes 
to activate transcription (Barboric et al., 2001; Jang et al., 2005; 
Devaiah et al., 2012). The ET domain of BRD4 independently 
recruits transcriptional activators such as NSD3 (a histone 
methyl transferase), JMJD6 (a histone arginine demethylase), 
and CHD4 (the catalytic subunit of the NuRD chromatin 
remodeler) or P300 (acetyl transferase) (Taniguchi, 2016). 
Subsequent studies reported that BRD4 binds to acetylated 
histones in the enhancers or promoter regions of inflammatory 
genes (Lovén et al., 2013). In addition, BRD4 has intrinsic kinase 
activity and phosphorylates the Pol II CTD at the Ser2 position; 
these results indicate a clear role for BRD4 in the regulation 
of transcription (Devaiah et al., 2012). BRD4 can also bind to 
acetylated residues in other proteins besides histones. Among 
these proteins, transcription factors have special relevance, as 
they are an additional mechanism by which BET can regulate 
gene transcription (Wu and Chiang, 2007; Alpatov et al., 2014). 
The most widely investigated is the transcription factor nuclear 
factor-κB (NF-κB). Studies in cancer have found that NF-κB 
is regulated by BRD4, acting as a coactivator, by binding to 
acetylated lysine-310 residue of the RelA NF-κB subunit (Huang 
et al., 2009). In cancer cells, the binding of BDR4 to RelA/
NF-κB subunit blocks RelA ubiquitinilation and its subsequent 
proteasome-mediated degradation, leading to sustained nuclear 
NF-κB activation and, therefore, showing a mechanisms involved 
in aberrant cell proliferation (Wu et al., 2013; Zou et al., 2014).
Targeting BET Proteins as a Potential 
Source of Novel Therapeutic Options.
The development of drugs targeting BET proteins has attracted 
special interest. The BET protein inhibitors (iBETs) compete for 
the bromodomain binding pocket and displace BET proteins 
from the binding to acetylated lysine residues located in histones. 
This interrupts the remodeling of chromatin and prevents 
the expression of certain genes, therefore regulating cellular 
responses (Figure 3).
BET Proteins in the Regulation of Cell Proliferation: 
Potential Therapeutic Role in Cancer and 
Proliferative Disorders
One of the earliest iBETs described was JQ1. This compound 
acts as pan-specific BRD4 inhibitor that binds to both BD1 
and BD2 bromodomains in BRD4, therefore blocking its 
binding to acetylated lysine residues located in histones and 
other proteins (Maxmen et al., 2012). The first studies were 
done in experimental proliferative pathologies, including 
midline carcinoma and hematological malignances (Alqahtani 
et al., 2019). Initial studies showed that JQ1 exerted high 
antiproliferative responses associated with cell-growth arrest 
and senescence in experimental models of multiple myeloma 
(Delmore et al., 2011), and described that JQ1 mainly target 
c-Myc expression (Bandukwala et al., 2012). Since then, many 
preclinical studies have shown that JQ1 exerts beneficial effects in 
FIGURE 3 | Bromodomain and extraterminal (BET) proteins regulate cellular processes such as cell cycle, proliferation, differentiation, inflammation, and fibrosis. 
JQ1 binds to BRD4, this situation not allows the recruitment of p65 and finally it is ubiquitinilated and degraded by the proteasome. BRD4 interacts with NF-kB to 
induce the expression of genes associated with processes such as inflammation or TH17 immune response.
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different proliferative disorders (Bandukwala et al., 2012; White 
et al., 2019), and in other pathologies, as it will be discussed later. 
Interestingly, in a murine model of polycystic kidney disease, JQ1 
delayed cyst growth, by inhibiting c-Myc gene expression and 
cystic epithelial cell proliferation (Zhou et  al., 2015). However, 
this iBET cannot be used in humans due to its pharmacological 
properties. Nowadays, there is a large battery of iBETs developed 
by diverse pharmaceutical companies. Most of them have been 
tested in different experimental malignances, and some of them 
currently tested on clinical trials (as it will be discussed latter).
BET Proteins in Inflammation and Immune 
Responses in Renal Diseases
Potential Role of iBETS as Anti-Inflammatory Drugs 
via Inhibition of Proinflammatory Gene Expression
Many in vitro studies have found that BET proteins regulate 
the transcription of proinflammatory genes. BRD4 binds to 
acetylated histones in the enhancers or promoter regions of 
inflammatory genes (Lovén et al., 2013), as demonstrated for 
IL-6, CCL-2, and CCL-5 in renal cells (Suarez-Alvarez et al., 
2017). In activated macrophages, JQ1 and I-BET reduced LPS-
mediated gene upregulation of cytokines (TNF-α and IL-6) 
and chemokines (CCL-2) (Nicodeme et al., 2010; Belkina et al., 
2013), as observed in Raw 267.4 cells treated with JQ1 (Meng 
et al., 2014). In synovial fibroblasts obtained from rheumatoid 
arthritis patients, iBET-151 diminished their capacity to recruit 
immune cells by the inhibition of CXCL10 and CXCL11 (Klein 
et al., 2016). In human endothelial cells a novel iBET specific 
for BD2, apabetalone (initially named RVX-208), also reduced 
the gene expression of VCAM-1 and CCL2 induced by TNF-α 
or LPS (Jahagirdar et al., 2014). Using a whole-genome gene 
expression array, our group reported that in activated renal cells, 
JQ1 decreased TNF-α-mediated overexpression of several genes 
involved in the regulation of the inflammatory process and the 
immune response. These in vitro data suggested that iBETs could 
be used as anti-inflammatory drugs.
Anti-inflammatory properties of iBETs have been observed 
in different preclinical studies. Most of the studies have been 
done using the pan-specific iBET JQ1 in preventive therapeutic 
treatment (Liu et al., 2014; Zhang et al., 2015). In a collagen-
induced experimental arthritis model, JQ1 induced attenuation 
in the arthritis severity score associated to lower serum levels 
of proinflammatory cytokines, including IL-1β, IL-6, IL-17, 
and IL-18 (Zhang et al., 2015). Another study in experimental 
periodontitis showed that JQ1 reduced bone destruction 
and decreased proinflammatory cytokine expression (IL-1β, 
IL-6, TNF-α, and IL-17) (Meng et al., 2014). In a model of 
experimental atherosclerosis in hyperlipidemic ApoE-deficient 
mice treatment with the BD2 inhibitor apabetalone reduced 
the aortic lesion formation, decreased circulating adhesion 
molecules (haptoglobin, VCAM-1, IL-18, SAP, and M1P1a) and 
reduced mRNA levels of proinflammatory cytokines (IL-6 and 
VCAM1) in carotid tissue (Jahagirdar et al., 2014). In different 
experimental models of renal damage, including unilateral 
uretheral obstruction (UUO), infusion of Angiotensin II (AngII) 
and immune-mediated glomerulonephritis, JQ1 inhibited 
proinflammatory gene expression associated to the diminution 
of the presence of inflammatory cells in the damaged kidneys. 
Moreover, by chromatin-immunoprecipitation experiments, we 
demonstrated that JQ1 displaces BRD4 binding to the acetylated-
histone H3 in the promoter region of the proinflammatory genes 
IL-6, CCL-2, and CCL-5 (Suarez-Alvarez et al., 2017), showing 
a mechanism involved in these anti-inflammatory properties of 
iBETs in experimental renal diseases (Figure 3).
Potential Role of IBETS as Anti-Inflammatory Drugs 
in Renal Diseases via Inhibition of the Transcription 
Factor NF-κB
BET proteins can also bind to acetylated residues in transcription 
factors. The NF-κB pathway is a key transcription factor involved 
in the regulation of renal inflammation. In experimental and 
human renal diseases, the renal activation of the NF-κB pathway 
is associated with the overexpression of proinflammatory 
mediators, as initially described in human biopsies of diabetic 
nephropathy patients, showing colocalization of activated NF-κB 
and upregulation of CCL2 mRNA expression levels (Mezzano 
et al., 2004). Many experimental investigations have described 
that NF-κB inhibition, by different strategies, including blocking 
specific components of this pathway, or indirectly by drugs 
used in the clinic to treat CKD patients, such as blockers of the 
renin angiotensin system, diminishes renal inflammation, and 
ameliorates disease progression (Sanz et al., 2010; Chung and 
Lan, 2011). The RelA NF-κB subunit can be acetylated in lysine 
310 leading to its activation. As commented before, studies done 
in proliferative disorders have described that BRD4 binding to 
acetylated lysine-310 of RelA is essential to activate specific NF-κB 
target genes (Amir-Zilberstein et al., 2007; Huang et al., 2009; Zou 
et al., 2014). In an experimental diabetic model of renal damage 
in db/db mice, increased NF-κB was described and in podocytes 
stimulated with AGE, the treatment with the BET inhibitor 
MS417 suppressed acetylation of Stat3 and NF-κB. (Liu et al., 
2014). Interestingly, we have observed that BET inhibition with 
JQ1 reduced RelA nuclear levels in several experimental models 
of renal damage and in TNF-α-treated renal cells, and thereby 
blocked NF-κB transcriptional activation and downregulated 
several NF-κB-controlled genes, including CCL-2 and IL-17A 
(Suarez-Alvarez et al., 2017), suggesting another mechanism 
contributing to the anti-inflammatory effects of iBETs in renal 
damage (Figure 3). Other iBETs also blocked NF-κB pathway and 
diminished renal inflammation. In the UUO model, treatment 
with I-BET151 (specific inhibitor against BRD2, BRD3, and 
BRD4) suppresses the phosphorylation and acetylation of 
NF-κB associated with a decrease in the number of CD68+ 
cells (macrophages) located in tubulointerstitium (Xiong et al., 
2016). Moreover, I-BET151 also reduced the phosphorylation of 
STAT3 and the MAP kinases Erk1/Erk2 after UUO, but the direct 
effect of iBET in these pathways has not been demonstrated 
(Xiong et al., 2016). Interestingly, in vitro data showed that JQ1 
specifically block active NF-κB, as shown by the degradation 
of RelA nuclear levels, without changing phosphorylated RelA 
levels in the cytosol (Figure 3). Moreover, the results of the DNA-
array analysis showed that BET inhibition mainly downregulates 
proinflammatory genes, while genes controlling several NF-κB 
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pathway components, such as the NF-kB subunits p50, RelA, 
RelB, IKB, and A20/TNFAIP3, were not modify (Suarez-Alvarez 
et al., 2017). Similar findings were described in the regulation 
of A20/TNFAIP3 (Huang et al., 2009). These results suggest that 
iBETs could be a unique pharmacological strategy to block the 
active NF-κB via the blockade of the interaction of BRD4 with 
nuclear acetylated-RelA. This strategy could be a more selective 
anti-inflammatory option, that other NF-κB targeting-drugs, 
such as kinase inhibitors or proteasome-targeted drugs.
Potential Role of iBETS as Anti-Inflammatory  
Drugs in Renal Diseases via TH17 Immune 
Response Modulation
Epigenetic regulation of cytokines and transcription factors has 
been shown to be important in directing lineage differentiation 
of CD4 T lymphocytes to Th1, Th2, Th17, or regulatory T cells, 
which determines the immune response. BRD4 participates in 
the differentiation of naïve CD4 T lymphocytes into Th17 cells 
(Cheung et al., 2017). Different BET inhibitors, such as MS417, 
JQ1, and I-BET762 can inhibit T-helper-cell differentiation by 
blocking the specific transcriptional activation of the specific 
factors. These iBETs blocked the transcription factor RORγT 
and inhibited IL-17 gene expression in Th17 cells, and inhibited 
TBX21 and INFγ gene in Th1 cells, but also had small effects 
on GATA3 and IL4 gene expression in Th2 cells (Cheung et al., 
2017).
The role of Th17 cells and its main effector cytokine IL-17A 
in immune-mediated and chronic inflammatory renal diseases 
has increasing importance. Many experimental studies targeting 
Th17 immune response by different approaches, including 
neutralizing antibodies against IL17A or its soluble receptor, 
pharmacological inhibitors of RORऔT, as well as studies using 
genetically modified mice, have underscored the importance 
of IL17A in the pathogenesis of chronic inflammatory diseases, 
including immune and nonimmune renal damage (Bäckdahl 
et  al., 2009; Edgerton et al., 2009; Pindjakova et al., 2012; 
Mele  et al., 2013; Rodrigues-Díez et al., 2013; Mease et al., 2014; 
Park et al., 2014; Isailovic et al., 2015) Recently, we described 
that in an experimental model of diabetic nephropathy in BTBR 
ob/ob (leptin deficiency mutation) mice administration of an 
IL-17A neutralizing antibody, when renal dysfunction and 
structural alterations had already started, caused a beneficial 
effect, restoring renal damage parameters, mainly by inhibition of 
NF-κB/inflammation in the diabetic kidney (Lavoz et al., 2019). 
Moreover, treatments blocking IL-17A have shown beneficial 
effects in human clinical trials for the treatment of ankylosing 
spondylitis, chronic plaque psoriasis, and psoriatic arthritis and 
are currently tested in other inflammatory diseases (Leonardi 
et al., 2012; Baeten et al., 2013; Baeten et al., 2015; Mease et al., 
2015). In two models of experimental renal damage, unilateral 
ureteral obstruction and immune mediated glomerulonephritis 
by nephrotoxic serum, we described that BET inhibition by JQ1 
treatment markedly diminished the presence of IL17A expressing 
cells in the injured kidneys, associated with downregulation of 
renal levels of IL17A and other Th17-related cytokines, such as 
CCL-20 and CSF-1 (Suarez-Alvarez et al., 2017). These data suggest 
that BET inhibition could exert beneficial effects on renal damage 
by modulating the Th17 immune response (Figure 3). There are 
studies about the effect of BET pharmacological inhibition on 
different pathologies associated with Th17 response, results that 
support these data, as described in colitis (Cheung et al., 2017), 
experimental autoimmune encephalomyelitis (Jahagirdar et al., 
2017a), retinal inflammatory disease (Eskandarpour et al., 2017), 
and asthma (Nadeem et al., 2018).
Besides regulating Th17 differentiation, BET proteins can also 
modulate Th17 response by a direct effect on the transcription of 
the IL17A gene. BRD4 and BRD2 bind to the regulatory region of 
CNS2 that controls IL-17A transcription (Mele et al., 2013). The 
treatment with JQ1 in a model of renal damage, downregulated 
IL17A gene, showing that this mechanism is also operating in 
injured kidneys (Suarez-Alvarez et al., 2017). Moreover, in Th17 
cells a transcriptional coactivator such as p300 was able to bind to 
the IL-17A gene promoter supplying easier access to chromatin 
(Wang et al., 2012). All data suggest that BET inhibition could 
be an additional therapeutic option to block the inflammatory 
effects mediated by IL-17A in the kidney.
BET Proteins in Renal Fibrosis
Several preclinical studies s suggest that iBETs can also present 
antifibrotic properties, as described in pulmonary (Tang et al., 
2013), liver (Ding et al., 2015), cardiac (Spiltoir et al., 2013), and 
renal (Xiong et al., 2016; Zhou et al., 2017; Wang et al., 2018) 
fibrosis. In a mouse model of bleomycin-induced lung fibrosis, 
mouse treated with JQ1 had less collagen I deposition compared 
to control values (Tang et al., 2013). In this study the evaluation 
of lung fibroblasts isolated from patients with idiopathic 
pulmonary fibrosis (IPF) or healthy donors demonstrated 
that JQ1 ameliorated the phenotypic changes induced by the 
disease, such as increased cellular migration and proliferation. 
They found that JQ1 inhibited the secretion of IL-6, and they 
described an association between Ac-H4K5 and Brd4 involved 
in IL-6 gene regulation, therefore suggesting that iBET-mediated 
phenotypic changes could be mediated by IL-6 regulation (Tang 
et al., 2013). In a carbon tetrachloride (CCl4) mouse model 
of liver injury, the animals injected with JQ1 presented lower 
fibrosis and diminished expression of markers of hepatic stellate 
cell activation. Moreover, the in vitro evaluation of three different 
BET inhibitors (JQ1, I-BET-151, and PFI-1) showed a decrease 
of gene expression of fibrotic and hepatic stellate cell activation 
markers, such as type 1 collagen, α-smooth muscle actin 
(α-SMA), and desmin. In addition, JQ1 pretreatment abolished 
TGF-beta-induced fibroblast-like morphology changes in 
cultured hepatic stellate cell (Ding et al., 2015). (Spiltoir et al., 
2013) showed that cardiac hypertrophy was significantly reduced 
by JQ1 in primary neonatal rat ventricular myocytes treated with 
phenylephrine or phorbol-12-myristate-13-acetate, determined 
by changes in atrial natriuretic factor levels. The in vivo effect 
of JQ1 on cardiac remodeling was demonstrated in a transverse 
aortic constriction model. JQ1 treatment reduced left ventricular 
systolic dysfunction, atrial natriuretic factor expression levels 
and interstitial fibrosis (Spiltoir et al., 2013). Other studies also 
confirm the beneficial effect of JQ1 in fibrosis and inflammation 
consequent to the radiation used in radiotherapy in thoracic 
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cancer, by suppressing BRD4, c-MYC, p65 activation collagen 
I, TGF-β, and phosphorylated-SMAD2/3 after irradiation (Jung 
et al., 2015). Other BET inhibitor, RVX-297, specific for BD2, 
also diminished fibrosis in experimental models of arthritis 
(Jahagirdar et al., 2017b).
In the experimental model of UUO-induced renal damage 
several studies have observed that treatment with different iBETs, 
I-BET151, and JQ1, diminished renal fibrosis (Xiong et al., 2016; 
Zhou et al., 2017). However, as commented before, JQ1 also exert 
anti-inflammatory effects in UUO model, as renal inflammation 
occurs earlier than ECM accumulation, the amelioration of 
renal fibrosis described in this model could be subsequent to 
the inhibition of renal inflammation. Hypertensive nephropathy 
is one of the most common secondary nephropathies that 
trigger fibrosis in the kidney. A study performed in human 
kidney biopsies from hypertensive nephropathy patients 
and in an experimental of hypertension induced by systemic 
administration of AngII, described that BRD4 protein levels 
were upregulated in human and mouse kidney samples. Mice 
treatment of JQ1 diminished AngII-induced kidney fibrosis 
(Wang et al., 2019). However, as commented in the UUO model, 
previous studies have found that JQ1 treatment also diminished 
renal inflammation after 3 days of AngII administration 
(Suarez-Alvarez et al., 2017). Future studies should be done to 
study the direct effect of iBETs in experimental renal fibrosis, to 
clearly elucidate whether these compounds could block or even 
reverse the progression of renal fibrosis, independently of their 
anti-inflammatory effects. In fact, in all the experimental studies 
iBET treatment was started before renal damage occurs, and 
there is a lack of therapeutic interventions.
Several in vitro data have demonstrated direct antifibrotic 
effects of iBETs in renal cells. Studies using the cell line NRK-
49F of rat renal fibroblasts showed that I-BET151 inhibited cell 
activation and proliferation, measured by the expression levels 
of α-SMA, and diminished ECM proteins overexpression, 
including collagen I and fibronectin (Xiong et al., 2016). 
Accordingly, BRD4 gene silencing inhibited TGF-β1 induced 
renal fibroblasts activation (Zhou et al., 2017). Moreover, in vitro 
studies in tubular epithelial cells stimulated with TGF-β1, showed 
that BRD4 inhibition, by gene silencing or treatment with JQ1, 
downregulated the expression of fibrotic-related genes, such 
as α-SMA and fibronectin, collagen IV, and fibronectin (Zhou 
et al., 2017). In pathological conditions, tubular epithelial cells 
can be damaged, causing death, by apoptosis/necrosis, or if there 
is on sublethal damage leads to a phenotype conversion, named 
epithelial-to-mesenchymal transition (EMT). In the context 
of renal damage, partial EMT is characterized by phenotypic 
changes leading to the loss of epithelial cell properties, the 
acquisition of mesenchymal markers (such as α-SMA), and 
induction of an aberrant senescence–secretome characterized 
by the production of proinflammatory and profibrotic proteins, 
that can contribute to renal fibrosis (Lovisa et al., 2016). 
Therefore, pharmacological interventions targeting partial 
EMT could be used as antifibrotic treatments for renal diseases. 
In vitro studies have found that JQ1 restored EMT-related 
changes induced by TGF-β1 in tubular epithelial cells (Wang 
et al., 2018). Moreover, in activated tubular epithelial cells, JQ1 
inhibited a large array of mediators, some of them belonging to 
senescence–secretome, as IL-6 (Suarez-Alvarez et al., 2017). In 
experimental fibrosis induced by AngII-induced renal damage 
JQ1 restored changes in EMT-related proteins (suppressed 
the expression of vimentin, but increased the expression of 
epithelial markers such as E-cadherin and Zo-1) (Wang et al., 
2019). In other pathologies, BRD4 inhibition suppresses EMT, 
as described in breast cancer cells (Shi and Vakoc, 2014). 
NF-κB regulates genes involved in EMT, including snail family 
transcriptional repressor (Tian et al., 2018), showing another 
target of iBETs in the regulation of EMT. Cardiac fibrosis 
contributes to the pathogenesis of cardiovascular diseases 
through endothelial–mesenchymal transition (EndMT). In 
a model of transverse aortic constriction, BRD4 expression 
was upregulated in endothelial cells. In cultured endothelial 
cells the pharmacological or genic blockade of BRD4 by JQ1 
or shRNAs, respectively, attenuated TGF-β-induced EndMT 
(Song et al., 2019a). These data show an important role of BRD4 
in the modulation of phenotype conversion, and suggest that 
iBETs could act as anti-fibrotic drugs inhibiting partial EMT in 
renal injury.
The Smad signaling pathway is the main mechanism involved 
in the regulation of fibrosis (Meng et al., 2016; Hu et al., 2018). 
Some authors linked the epigenetic molecule BRD4 with TGF-β/
Smad signaling pathway (Figure 4). In a model of cardiac 
hypertrophy induced by aquatic physical training, transcriptomic 
analysis of JQ1 regulated showed downregulation of many genes 
under TGF-β control (Duan et al., 2017). In UUO model, mice 
treated with I-BET151 presented a downregulation in gene 
expression of α-SMA, a marker of activated miofibroblasts, and 
decreased fibronectin/collagen deposition in obstructed kidneys, 
associated to a diminution of phosphorylated-Smad3 expression 
whereas Smad7 expression levels were unchanged (Xiong et al., 
2016)Therefore, TGF-β/Smad3 signaling deactivation might 
explain the antifibrotic effects of JQ1, via gene expression 
downregulating of several profibrotic factors. However, more 
detailed mechanistic experiments should be done to demonstrate 
the specific effect of iBET on the regulation of Smad pathway 
activation in renal diseases.
iBETs as Potential Therapeutic Targets for 
Renal Diseases
The most important feature of chronic renal diseases is the 
functional deterioration of renal structures, and finally, the loss of 
renal function. Some experimental studies have investigated the 
effect of iBETs in renal function and structure. In a immune-model 
of progressive renal damage induced by glomerular antibasement 
membrane nephrotoxic serum, JQ1 treatment improved serum 
creatinine levels and urinary albumin to creatinine ratio, both 
biochemical parameters to evaluate renal function, and delayed 
the appearance of glomerular structural damage (extracapilary 
proliferation and fibrinoid necrosis) (Suarez-Alvarez et al., 2017). 
In another study in a model of acute kidney injury induced by the 
nephrotoxic cisplatin, JQ1 restored changes in renal function (as 
serum creatinine and BUN levels) and ameliorated renal lesions 
(hyaline cast formation and renal tubule lysis) (Sun et al., 2018b). 
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In a model of autosomal dominant polycystic kidney disease 
in mouse strains with Pkd1 (pyruvate dehydrogenase kinase 
isozyme 1) mutations, JQ1 treatment strikingly delayed cyst 
growth and kidney enlargement, and preserved renal function 
through c-Myc–p21 signaling pathway modulation (Zhou et al., 
2015). These studies demonstrated the beneficial effect of iBETs 
in the preservation of renal function in different experimental 
models of renal diseases.
BET Proteins and Endothelial Dysfunction 
Associated to CvD–CKD
Endothelial dysfunction is one of the first events observed in 
CKD and cardiovascular disease (CVD) (Martens and Edwards, 
2011). The loss of an adequate function of the endothelium, which 
regulates the interaction of cells and circulating proteins with the 
resident cells of the vascular wall, affects vascular homeostasis, 
thus promoting the beginning of the vascular damage (McCarron 
et al., 2019). As described above, iBETs regulate the inflammatory 
response. A study conducted in primary human pulmonary 
microvascular endothelial cells (HPMECs) from healthy donors 
showed that JQ1 decreased mRNA and protein levels of IL6 and 
IL8 and diminished the recruitment of p65 NF-κB to IL6 and 
IL8 promoters. The same study reported that the treatment of 
the cells with JQ1 inhibited the proliferation and migration of 
HPMECs and prevented its cell cycle progression (Mumby et al., 
2017). In a model of acute lung inflammation and in HUVECs 
stimulated with TNF-α or LPS, JQ1 reduced the expression of 
inflammatory factors (IL-6 and IL-8) and adhesion molecules 
(ICAM-1, VCAM-1 and E-selectin) (Huang et al., 2017). 
However, there are no studies evaluating whether BET inhibition 
could directly, or not, modulate on vascular reactivity and 
functionality, including key mechanism involved in this process, 
such as the redox signaling or kinases activation.
BET Proteins in Cardiovascular 
Pathologies as Subjacent Pathologies 
to CKD
Cardiovascular events are some of the main causes of death in 
CKD patients. There are several studies about the contradictory 
role of BET inhibitors in the improvement/impairment of the 
pathological features of heart failure (HF). Several data report 
that BRD4 is an important activator of gene transactivation 
during pathologies that lead to cardiac hypertrophy (Meng et al., 
2014; Park-Min et al., 2014). A study performed in neonatal 
rat ventricular cardiomyocytes showed that several iBET 
I-BET-151, PFI-1 (a selective inhibidor against BRD4), and 
apabetalone reduced cardiomyocyte hypertrophy (Anand et al., 
2013). In a model of transverse aortic constriction in mice, JQ1 
attenuated multiple main features of heart failure by diminution 
of associated genes (Myh7, CTGF, Nppa, Nppb, and Rcan1) 
(Duan et al., 2017). In a model of ligation of the proximal left 
anterior descending coronary artery, BET inhibition ameliorated 
FIGURE 4 | BRD4 is involved in the transforming growth factor β (TGF-ß)/SMAD signaling pathway. BRD4 interacts with the components of this signaling pathway 
to regulate the expression of genes related to the synthesis of extracellular matrix proteins (MEC) and fibrosis.
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cardiomyocytes hypertrophy and fibrosis (Duan et al., 2017). 
However, there is one study showing the deleterious effect of 
BET inhibition, specifically IBET-151. In this study IBET-151 
induced impairment of heart function determined by a reduced 
right and left ventricular fractional shortening and a decrease 
in the velocity-time-integral in the aorta and pulmonary artery, 
associated with induced structural and functional alterations 
of the heart mitochondria analyzed by transmission electron 
microscopy (Piquereau et al., 2019). These results suggest that 
more deeply studies will be necessary in the future in this field.
BET Proteins in vascular Calcification as a 
Secondary Effect of CKD
In CKD patients vascular calcification in a common complication 
characterized by important calcium phosphate deposits in the 
blood vessels walls. During this process, the vascular smooth 
muscle cells differentiated into osteoblasts, creating calcium 
deposits that compromise the elasticity of the vascular wall (Moe 
and Chen, 2004; Alves et al., 2014). There are several treatments 
for vascular calcification, such as inhibitors of phosphate binders 
or calcimimetics (Iyemere et al., 2006), but recently iBETs has 
been tested as a novel approach to this problem. Apabetalone 
has been shown to reduce serum alkaline phosphatase (ALP) in 
CKD patients with a history of cardiovascular events (Kulikowski 
et al., 2018). There are previous references about the role of ALP 
with adverse cardiovascular outcomes in CKD patients that 
normally developed vascular calcification (Haarhaus et al., 2017) 
(Taliercio et al., 2013). However, the role of ALP is complex and 
will require future investigations. A recent study has shown that 
apabetalone prevented matrix mineralization of cultured primary 
human coronary artery VSMCs by targeting ALP gene expression 
(Gilham et al., 2019). In this in vitro study, apabetalone through an 
epigenetic mechanism diminished several procalcific genes which 
drives vascular smooth muscle cell transdifferentiation (ALP and 
RUNX2). These authors demonstrate that BRD4 is redistributed 
on chromatin during transdifferentiation to alter gene expression 
and generate unique BRD4-rich enhancers associated with 
calcification (Gilham et al., 2019). However, the investigation of 
the involvement of iBETs in additional mechanism activated in 
vascular calcification, such as downregulation of the expression of 
genes involved in inflammation, or noncanonical WNT signaling, 
will require future investigations. There are some ongoing clinical 
trials that will give us information about the effects of iBETs on 
vascular calcification and other cardiovascular complications in 
CKD patients.
BET Proteins and miRNAs 
Profile Associated
Functional roles for miRNAs have been described in numerous 
biological processes that include differentiation, development, 
cell proliferation, and apoptosis. (Erson & Petty, 2008; Stefani and 
Slack, 2008; Garzon et al., 2009). It is evident that miRNAs play a 
critical role in the maintenance of normal tissue homeostasis, so 
changes in their expression are of high relevance in pathological 
processes. Recent evidence indicates that miRNAs play a 
fundamental role in the regulation of cellular and molecular 
processes involved in renal and vascular diseases (Gebeshuber 
et al., 2013; Laffont & Rayner, 2017). An RNA sequencing study 
performed in endothelial cells showed miRNAs transcriptional 
profile changes induced by TNF-α that could be regulated by 
iBETs. TNF-α induced the upregulation of 44 miRNAs, such as 
mir 146a, mir-155, mir-455, mir-887, and mir-377. Interestingly, 
pretreatment of the cells with JQ1 downregulated TNF-α-
mediated overexpression of mir-146a and mir-155. This study also 
demonstrated that BRD4 was recruited to the upstream gene loci 
of miR-146a and miR-155 and BRD4 gene deletion modulated 
pri-miR-146a and miR-155HG expression. In addition, using an 
inflammatory model induced by LPS, they found that mice treated 
with agomirs of miR-146a and miR-155 showed downregulation 
of inflammatory genes, such as VCAM-1, Selectin, and TRAF6, 
and decreased the number of circulating leukocytes (Duan 
et al., 2016). This study points that miR-146a and miR-155 play 
a key role in renal inflammation, and suggest that can be target 
of iBETs. A study in oligodendrocyte-precursor cells (OPCs) 
injured by regulating oxygen/glucose deprivation (OGD) showed 
that miR-146b-5p expression was reduced. The overexpression 
of miR-146b-5p induced cell growth and viability, and reduced 
the apoptosis and oxidative stress in OPCs submitted to OGD. 
In these cells BRD4 expression was diminished by miR-146b-5p. 
Moreover, the BRD4 silencing with a siRNA showed a protective 
effect in OGD-injured OPCs and modulated the Keap1/Nrf2/
ARE signaling pathway (Li et al., 2019).
MiRNA-29 is a key regulator of pulmonary (Tang et al., 
2019), liver (Huang et al., 2019), and renal fibrosis (Huang 
et al., 2019). The analysis of the miRNA signature linked to BET 
proteins in chronic obstructive pulmonary disease demonstrated 
that these patients presented a reduced miR-29b plasma levels 
associated with an increase of BRD4 levels. miR-29b levels in 
these patients were correlated with pulmonary function and 
inflammation and IL-8 expression (Tang et al., 2019). A study 
in streptozotocin-induced diabetic mice demonstrated that 
miR-29a overexpression by lentiviral infection acts as a positive 
regulator of Wnt/β-catenin signaling in mesangial cells and 
protects cell from apoptosis and fibrosis induced by diabetes (Hsu 
et al., 2016); but currently, there is no renal studies that link this 
specific miRNA with the modulation of BET proteins. Another 
study of cholestatic liver fibrosis induced by bile duct-ligation 
showed that mice overexpressed miR-29a decreased fibrosis 
(determined by α-SMA expression) and reduced the expression 
of hepatic BRD4 and SNAI1 in cholestatic livers. In hepatic 
stellated cells, miR-29a overexpression diminished the protein 
levels and gene expression of EZH2, MeCP2, and SNAI1 and 
increased PPAR-γ. Similarly, JQ1 reduced C-MYC, EZH2, and 
SNAI1 expression. Both, mimic miR-29a and JQ1 treatments, 
inhibited hepatic stellated cells migration and proliferation 
(Huang et al., 2019). There are several studies about the miRNA 
profile that regulate BET proteins in several oncological 
pathologies such as gastric cancer (Song et al., 2019b), cutaneous 
T-cell lymphomas (Kohnken et al., 2019), hepatocellular 
carcinoma (He et al., 2018), or prostate cancer (Guan et al., 
2019). In a study performed in diffuse large B-cell lymphoma, 
cells treated with the iBET OTX015 revealed modifications in 
the expression levels of miR-92a-1-5p, miR-21-3p, miR-155-5p, 
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and miR-96-5p. These miRNAs are involved in the modulation 
of different signaling pathways such as p53, apoptosis, MYC-
targets, cell cycle regulation, B-cell receptor signaling, IL-6 
signaling, the STAT3, PI3K, and NF-κB pathways (Mensah 
et al., 2018). Some of these miRNAs have a relevant role in renal 
pathology. Administration of an anti-miR-92a after crescentic 
rapidly progressive glomerulonephritis prevented albuminuria 
and kidney failure, by the modulation cyclin-dependent kinase 
inhibitor p57Kip2, indicating miR-92a inhibition as a potential 
therapeutic strategy for this renal disease (Henique et al., 2017). 
There are also some studies about the deleterious role of miR-92a 
related with vascular damage in CKD associated to endothelial 
dysfunction (Shang et al., 2017) or with the renal damage 
progression associated to atherosclerosis (Wiese et al., 2019). 
miR-155-5p is described as a key target of tubular renal cell 
injury in response to high glucose exposition in vitro modulating 
p53, sirt1 signaling pathway, and autophagy process (Wang et al., 
2018). In relation with miR-21, there are  several studies in 
experimental models of renal damage, diabetic nephropathy, or 
hypertension, that identified this miRNA as a key modulator of 
renal damage and fibrosis (Tang et al., 2019) (Song et al., 2018); 
(Wang et al., 2014); (Kölling et al., 2017); (Chen et al., 2017); (Hu 
et al., 2014) but there is no studies about its relationship with 
BET proteins in this field of study. Instead, a study in SW480 
colon cancer mouse xenografts showed that treatment with JQ1 
significantly downregulated miR-21 and reduced tumor growth 
and naked cuticle homolog 2 (Nkd2) expression and increased 
the apoptosis and β-catenin levels (Zhang et al., 2018). Another 
study in gastric cancer cells demonstrated that JQ1 reduced 
the proliferation and invasiveness of cancer cells through the 
induction of cellular senescence (increased cellular SA-β-Gal 
activity and elevated p21 levels). The authors also showed that 
p21 levels were modulated by miR-106b-5p. The overexpression 
of miR-106b-5p diminished JQ1-induced p21 expression and 
cellular senescence (Dong et al., 2018). All these results reveal 
that there is an extensive miRNA signature associated with the 
modulation of BET proteins in several proliferative disorders. In 
despite, there are not many studies about these proteins in the 
renal disease field. The modulation of BET proteins through 
miRNAs could be a therapeutic option to reverse the key 
pathological processes in the progression of renal disease such 
as the inflammatory response (modulating proinflammatory 
factors and inflammatory cell infiltration in the kidney), the 
apoptosis, oxidative stress, and fibrosis.
iBETs in Clinical Trials
There are now more than 23 ongoing clinical trials evaluating 
the safety, the pharmacokinetics, and the pharmacodynamic 
effects of different iBETs in several pathologies. Variants of 
MK-8628/OTX-015 (MK-8628-002, MK-8628-003, MK-8628-
005, MK-8628-006), a potent BET inhibitor specific to BRD2/3/4 
developed by Oncoethix GmbH Corp and Merck Sharp & 
Dohme Corp., are currently tested in oncological diseases, 
such as advanced solid tumors, glioblastoma multiforme, and 
hematological malignancies (https://ClinicalTrials.gov/NCT
02259114,NCT02296476¸NCT02698189,NCT02698176). 
An open-label, multicenter, dose-escalation phase 1/1b study 
in patients with acute myelogenous leukemia or non-Hodgkin 
lymphoma is analyzing a novel BET inhibitor FT-1101 (specific 
against BRD2/3/4 and BRDT. Forma Therapeutics, Inc) 
(Home  - ClinicalTrials.gov. (n.d.), 2019) (https://ClinicalTrials.
gov/NCT02543879). Another multicentric study (phase Ib) 
has set out to evaluate RO6870810/TEN-010, given as mono- 
and combination therapy to patients with advanced multiple 
myeloma (https://ClinicalTrials.gov/NCT03068351.Hoffmann-
LaRoche). Other trials in progressive lymphoma and multiple 
myeloma patients studied the sequential dose escalation of BET 
inhibitor CPI-0610 (specific inhibitor against BD-1 of BRD2-4/
BRDT¸ Constellation Pharmaceuticals) (https://ClinicalTrials.
gov/NCT02157636).
The BD2 selective inhibitor Apabetalone (RVX-208/RVX000222), 
developed by Resverlogix, has been evaluated in patients with 
diabetes mellitus type 2 and with cardiovascular diseases of high 
risk (https://ClinicalTrials.gov/NCT02586155). In a recent report, 
the bioinformatics analysis about the impact of apabetalone on the 
plasma proteome in patients with impaired kidney function, showed 
that this iBET could modulated key molecular pathways involved 
in immunity and inflammation, oxidative stress, endothelial 
dysfunction, vascular calcification, and coagulation (Wasiak et al., 
2018). Fabry disease is a rare X-linked lysosomal storage disorder 
caused by mutations in the α-galactosidase A gene inducing 
severe complications, including cardiomyopathy and end-stage 
renal disease. There is an ongoing study by Resverlogix Corp. in 
patients with Fabry disease and CKD testing oral apabetalone 
administration on key biomarkers of vascular calcification, such as 
RANKL and osteoprotegerin, and key markers of inflammation. 
such as high-sensitivity C-reactive protein (https://ClinicalTrials.
gov/NCT03228940). The results of these ongoing clinical trials will 
help us to understand if BET inhibitors can be used in patients with 
cardiovascular and renal diseases (Figure 5).
New IBETs, the BET-PROTACs, have been developed. These 
are proteolysis-targeting chimera proteins, that recruit and 
utilize an E3-ubiquitin ligase to effectively degrade BET proteins. 
The treatment of mantle cell lymphoma cells with two different 
BET-PROTACs (ARV-771 and ARV-825), targeting BRD4 or 
BRD2/3/4, respectively, showed more potent apoptotic effect 
compared to iBET OTX015 (MK-8628), an iBET that selectively 
blocks BRD2/3/4. ARV-771 treatment inhibited in vivo growth 
and induced greater survival improvement of immune-depleted 
mice engrafted with mantle cell lymphoma cells (Sun et al., 
2018a). Other studies also described the role of BET-PROTACs 
in castration-resistant prostate cancer, using a cancer xenograft 
mouse model. In this model treatment with ARV-771, improved 
tumor progression and suppressed markers of poor prognosis, 
such as androgen receptor signaling (Raina et al., 2016).
The evaluation of preclinical studies and ongoing clinical 
trials revealed that, in some cases, treatment with BET-inhibitors 
presents adverse effects. An experimental study in mice developed 
by Bolden et al. showed that BRD4 blockade by reversible transgenic 
interference RNA (RNAi) has deleterious effects in several tissues, 
such as epidermal hyperplasia, alopecia, and decreased cellular 
diversity and stem cell depletion in the small intestine (Bolden et al., 
2014). In several clinical trials with diverse iBETs (NCT02391480; 
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NCT02516553; NCT01949883; NCT02296476; NCT01713582; 
NCT02683395), diverse side effects have been described, including 
gastric or intestinal located-toxicities (diarrhea, nausea, vomiting), 
fatigue, hyperbilirubinemia, thrombocytopenia, anemia, and 
in some cases kidney injury (Amorim et al, 2016; Berthon et al., 
2016; Hottinger et al., 2016; Aftimos et al., 2017; Blum et al., 2018; 
Patnaik et al., 2018).
New IBETs, the BET-PROTACs, have been developed. 
These are proteolysis-targeting chimera proteins that recruit 
and utilize an E3-ubiquitin ligase to effectively degrade BET 
proteins. The new BET-PROTACs have modifications in the 
molecular structure of the linker region of the PROTAC to 
optimize the blockade of bromodomains, improved cellular 
permeability, tissue distribution, and metabolism (Wang et al., 
2019). The treatment of mantle cell lymphoma cells with two 
different BET-PROTACs (ARV-771 and ARV-825), targeting 
BRD4 or BRD2/3/4, respectively, showed more potent apoptotic 
effect compared to iBET OTX015 (MK-8628), an iBET that 
selectively blocks BRD2/3/4. ARV-771 treatment inhibited 
in vivo growth and induced greater survival improvement of 
immune-depleted mice engrafted with mantle cell lymphoma 
cells (Sun et al., 2018a). Other studies also described the role 
of BET-PROTACs in castration-resistant prostate cancer, using 
a cancer xenograft mouse model. In this model treatment 
with ARV-771, result in improves tumor progression and a 
suppression of androgen receptor signaling which increased 
levels that are associated with a poor prognosis of the disease 
(Raina et al., 2016) (Figure 5).
Some clinical trials have shown a limited antitumor activity 
and secondary effects associated with cytotoxicity. These 
limitations suggest that new therapeutic approaches are needed 
to target BET proteins. Experimental studies have shown that 
BET inhibition versus BET degradation (BET-PROTACs) 
elicited different cellular effects and biological outcomes in 
proliferative disorders (Yang et al., 2019). These modifications of 
BET-PROTACs expected to have more profound effect on BET-
mediated transcriptional complexes and turn these inhibitors in 
the actual best option to improve the limited clinical efficacy of 
BET inhibitors and expand the field of use to other pathologies 
such as renal damage, in which epigenetic modifications have an 
important role in the pathology progress.
CONCLUSION AND PERSPECTIvES
Emerging evidence remark the importance environment 
modifications in the origin of pathological features in CKD 
and in the cardiovascular related complications. Some key 
processes implicated in the progression of renal disease such 
as inflammation and fibrosis have demonstrated that could 
induce epigenetic modifications associated to the deterioration 
of pathological process, highlighting the potential of epigenetic 
therapeutic strategies against BET proteins for CKD treatment. 
Preclinical studies have proven beneficial effects of iBETs in 
acute and chronic renal damage. The anti-inflammatory effects, 
by direct inhibition of gene expression and NF-KB activation, 
and the antifibrotic effects, by the inhibition of cell proliferation 
and phenotype changes, are, at least in part, responsible of 
these beneficial effects. New generation of BET inhibitors or 
degraders, more specific and less toxic, have been synthetized 
FIGURE 5 | Summary of the different bromodomain and extraterminal (BET) modulators in experimental/clinical studies in the context of several diseases including 
renal disease and the signaling pathways associated. iBETs interact with several signaling pathways to regulate inflammation and fibrosis.
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and now are submitted to preclinical and clinical studies. Their 
future findings will help us to elucidate all the beneficial or 
deleterious effect in several pathologies, being necessary to 
include studies in renal pathology.
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